Malignant Pleural Mesothelioma

Dr. Antonio Giordano is an Italian-American pathologist and geneticist, best known for his discovery of Rb2/p130, a tumor suppressor gene. Dr. Giordano is the president, founder and chairman of the board of the Sbarro Health Research Organization (SHRO), a nonprofit organization committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses, and to foster the training of young doctors in a spirit of professionalism and humanism. Dr. Giordano is also the founder and director of the SHRO supported Sbarro Institute for Cancer Research and Molecular Medicine, as well as the Center for Biotechnology, which are both located in Temple University's College of Science and Technology. Dr. Giordano is also a 'Chiara fama' professor of pathology in the Department of Medicine, Surgery, and Neuroscience at the University of Siena, Italy where the Temple Summer in Siena Biomedical Research program is based. Dr. Giordano earned his MD from the University of Naples in 1986, and he specialized in Pathology at the University of Trieste, earning his Ph.D in Pathology, summa cum laude. Dr. Renato Franco received his MD degree at Naples Federico II University in 1994 and completed his residency in Pathology in 1998. He obtained PhD in Anatomo-Pathological Science in 2003. His post-doctoral activity was developed in cancer biomarkers research and molecular pathology. Now in the National Cancer Institute of Naples his activity is directed to cancer diagnosis and cancer biomarkers research with prognostic and predictive value. Academic activity is related to teaching Histology and Histopathology in Nursing, Laboratories Technicians and Medical Biotechnology Faculties.

1. Epidemiology and surveillance evidence2. Multimodality Imaging assessment of Malignant Pleural Mesothelioma3. Surgery of Malignant Pleural Mesothelioma4. Diagnostic pathology of Malignant Pleural Mesothelioma: cytological, histological, immunohistochemical features5. Molecular mechanisms in the pathogenesis of Malignant Pleural Mesothelioma: predictive and prognostic factors6. The treatment of Malignant Pleural Mesothelioma: from the current standard to novel possible therapeutic strategies7. Future directions in Malignant Pleural Mesothelioma: an overview of the expert opinion